Effects of donor plasma and recipient characteristics on convalescent plasma treatment outcome of COVID-19

在缺乏FDA批准的药物治疗的情况下，恢复期血浆输注已迅速成为严重新冠肺炎患者的一种引人注目的紧急治疗方法。然而，由于这种治疗是在紧急情况下进行的，因此很少有人研究能够从这种输液中获益最大的供体血浆的特性和新冠肺炎患者的临床状况。我们组建了一个多学科团队，利用罗伯特·伍德·约翰逊大学医院的献血和输血计划以及最先进的资源，研究抗体反应和新冠肺炎严重程度的血浆标志物。该团队建议进行一项研究，将供者血浆属性(抗体效价和功能，以及抗原靶点)和受者的临床状况(包括外周血细胞免疫表型和各种新冠肺炎严重程度的血浆标志物)与恢复期血浆输注的成功与否联系起来。我们计划产生的新知识将指导制定合理的临床实践指南和设计恢复期血浆临床试验。

In the absence of FDA-approved pharmacological therapies, convalescent plasma infusion has rapidly emerged as a notable emergency therapy for severe cases of COVID-19. However, due to the emergency conditions under which this treatment has been practiced, little effort has been placed in characterizing the properties of the donor plasma and the clinical status of the COVID- 19 patients that can most benefit from the infusion. We have assembled a multidisciplinary team that leverages linked blood donation and blood transfusion programs at Robert Wood Johnson University Hospital and state-of-the-art resources for the study of antibody responses and plasma markers of COVID-19 severity. This team proposes to conduct a study that relates donor plasma properties (antibody titers and functions, and antigen targets) and recipient's clinical status (including peripheral blood cell immunophenotypes and various plasma markers of COVID-19 severity) to the success of convalescent plasma infusion. The new knowledge resulting from our plan will guide the development of rational clinical practice guidelines and the design of convalescent plasma clinical trials.